Ronny Renfurm

642 total citations
16 papers, 368 citations indexed

About

Ronny Renfurm is a scholar working on Nephrology, Cardiology and Cardiovascular Medicine and Hematology. According to data from OpenAlex, Ronny Renfurm has authored 16 papers receiving a total of 368 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Nephrology, 4 papers in Cardiology and Cardiovascular Medicine and 4 papers in Hematology. Recurrent topics in Ronny Renfurm's work include Renal Diseases and Glomerulopathies (6 papers), Platelet Disorders and Treatments (3 papers) and Atrial Fibrillation Management and Outcomes (3 papers). Ronny Renfurm is often cited by papers focused on Renal Diseases and Glomerulopathies (6 papers), Platelet Disorders and Treatments (3 papers) and Atrial Fibrillation Management and Outcomes (3 papers). Ronny Renfurm collaborates with scholars based in United States, Netherlands and Switzerland. Ronny Renfurm's co-authors include Alberto García-Hernández, Alexander Zarbock, Gregory Y.H. Lip, Thomas G. Gleason, Christopher B. Granger, J. Wouter Jukema, John A. Kellum, František Kovář, Philippe Gabríel Steg and Priyanka Priyanka and has published in prestigious journals such as New England Journal of Medicine, Biological Psychiatry and Journal of the American Society of Nephrology.

In The Last Decade

Ronny Renfurm

15 papers receiving 358 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ronny Renfurm United States 8 173 151 81 42 37 16 368
Mélanie Gaubert France 10 133 0.8× 79 0.5× 25 0.3× 81 1.9× 67 1.8× 20 348
Maximilian Tscharre Austria 10 167 1.0× 35 0.2× 43 0.5× 88 2.1× 38 1.0× 40 305
Hironori Miyahara Japan 10 115 0.7× 75 0.5× 17 0.2× 37 0.9× 28 0.8× 32 273
G. Symeonidis Greece 6 176 1.0× 26 0.2× 90 1.1× 41 1.0× 14 0.4× 7 398
Simina Selejan Germany 9 276 1.6× 31 0.2× 37 0.5× 133 3.2× 56 1.5× 11 458
Naoya Oketani Japan 17 445 2.6× 53 0.4× 42 0.5× 64 1.5× 109 2.9× 50 681
Osita Okafor United Kingdom 9 262 1.5× 41 0.3× 35 0.4× 76 1.8× 43 1.2× 21 409
Seçkin Satılmış Türkiye 10 145 0.8× 55 0.4× 16 0.2× 70 1.7× 44 1.2× 26 324
Shafik Khoury Israel 13 260 1.5× 62 0.4× 9 0.1× 81 1.9× 48 1.3× 48 443
Paolo Fabbrini Italy 11 188 1.1× 147 1.0× 6 0.1× 69 1.6× 68 1.8× 29 391

Countries citing papers authored by Ronny Renfurm

Since Specialization
Citations

This map shows the geographic impact of Ronny Renfurm's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronny Renfurm with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronny Renfurm more than expected).

Fields of papers citing papers by Ronny Renfurm

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronny Renfurm. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronny Renfurm. The network helps show where Ronny Renfurm may publish in the future.

Co-authorship network of co-authors of Ronny Renfurm

This figure shows the co-authorship network connecting the top 25 collaborators of Ronny Renfurm. A scholar is included among the top collaborators of Ronny Renfurm based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronny Renfurm. Ronny Renfurm is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Heerspink, Hiddo J.L., Alan G. Jardine, Donald E. Kohan, et al.. (2024). Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy. Kidney International Reports. 10(1). 217–226. 6 indexed citations
2.
Heerspink, Hiddo J.L., Meg Jardine, Donald E. Kohan, et al.. (2024). Atrasentan in Patients with IgA Nephropathy. New England Journal of Medicine. 392(6). 544–554. 27 indexed citations
3.
Rizk, Dana V., Dmitrij Kollins, Olympia Papachristofi, et al.. (2024). Safety and Efficacy of Iptacopan in Patients with IgA Nephropathy with Baseline eGFR 20 to <30 mL/min: Phase 3 APPLAUSE-IgAN Subcohort Results. Journal of the American Society of Nephrology. 35(10S). 1 indexed citations
4.
Perkovic, Vlado, Jonathan Barratt, Brad H. Rovin, et al.. (2024). Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy. New England Journal of Medicine. 392(6). 531–543. 42 indexed citations
5.
Perkovic, Vlado, Dmitrij Kollins, Olympia Papachristofi, et al.. (2024). #456 Efficacy and safety of iptacopan in patients with primary IgA nephropathy: interim analysis results of the Phase 3 APPLAUSE-IgAN study. Nephrology Dialysis Transplantation. 39(Supplement_1). 3 indexed citations
6.
Heerspink, Hiddo J.L., Meg Jardine, Donald E. Kohan, et al.. (2024). WCN24-2099 BASELINE CHARACTERISTICS OF THE ALIGN TRIAL: A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF ATRASENTAN IN PATIENTS WITH IGAN. Kidney International Reports. 9(4). S183–S183. 1 indexed citations
7.
Perkovic, Vlado, Dmitrij Kollins, Ronny Renfurm, et al.. (2024). WCN24-1506 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY. Kidney International Reports. 9(4). S506–S506. 4 indexed citations
8.
9.
Priyanka, Priyanka, Alexander Zarbock, Junichi Izawa, et al.. (2020). The impact of acute kidney injury by serum creatinine or urine output criteria on major adverse kidney events in cardiac surgery patients. Journal of Thoracic and Cardiovascular Surgery. 162(1). 143–151.e7. 79 indexed citations
10.
Nguyen, Quan Dong, Yasir J. Sepah, Brian B. Berger, et al.. (2019). Primary outcomes of the VIDI study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema. International Journal of Retina and Vitreous. 5(1). 28–28. 14 indexed citations
11.
Meersch, Melanie, Mira Küllmar, Ronny Renfurm, et al.. (2019). Vascular Adhesion Protein-1 Is Associated With Acute Kidney Injury in High-Risk Patients After Cardiac Surgery. Anesthesia & Analgesia. 129(6). 1474–1481. 2 indexed citations
12.
Zeeuw, Dick de, Ronny Renfurm, George L. Bakris, et al.. (2018). Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial. The Lancet Diabetes & Endocrinology. 6(12). 925–933. 40 indexed citations
13.
14.
Agnelli, Giancarlo, Alexander Gallus, Michael R. Lassen, et al.. (2013). Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). Thrombosis and Haemostasis. 112(2). 213–225. 10 indexed citations
15.
Steg, Philippe Gabríel, Shamir R. Mehta, J. Wouter Jukema, et al.. (2011). RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. European Heart Journal. 32(20). 2541–2554. 126 indexed citations
16.
Renfurm, Ronny, et al.. (1997). Anxiolytic and sleep improving effects of mirtazapine in everyday clinical practice. Biological Psychiatry. 42(1). 248S–248S. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mélanie Gaubert Breakdown of academic impact, for papers by Maximilian Tscharre Breakdown of academic impact, for papers by Hironori Miyahara Breakdown of academic impact, for papers by G. Symeonidis Breakdown of academic impact, for papers by Simina Selejan Breakdown of academic impact, for papers by Naoya Oketani Breakdown of academic impact, for papers by Osita Okafor Breakdown of academic impact, for papers by Seçkin Satılmış Breakdown of academic impact, for papers by Shafik Khoury Breakdown of academic impact, for papers by Paolo Fabbrini
Rankless by CCL
2026